AMENDMENT

In the Claims:

The following listing of claims will replace all prior versions and listings of the claims in the application:

Listing of the Claims:

Claims 1.-14. (Canceled).

- 15. (Previously Presented) A method for inhibiting PMN migration across columnar epithelia and inflammation in a subject comprising, administering to a subject an effective amount of a lipoxin A_4 compound, wherein the lipoxin compound is an analog of natural lipoxin A_4 , and wherein the analog of natural lipoxin A_4 has a metabolic transformation region different from the natural lipoxin A_4 resulting in a longer half-life than natural lipoxin A_4 .
 - 16. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

17. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

18. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

19. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

20. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

21. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

22. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

23. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

24. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

25. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

26. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

27. (Previously Presented) The method of claim 15, wherein the lipoxin analog is

where R' is H or CH₃.

28. (Canceled).